dioscin has been researched along with Bone Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, X; Chen, L; Cheng, C; Ding, Q; Liu, X; Mo, F; Peng, G; Wang, J; Yang, S; Zhang, W | 1 |
| Jia, Q; Li, W; Liu, W; Shen, J; Su, Q; Wang, Y; Yin, J; Zhang, J; Zhang, X; Zhao, Z | 1 |
2 other study(ies) available for dioscin and Bone Neoplasms
| Article | Year |
|---|---|
Dioscin inhibits the growth of human osteosarcoma by inducing G2/M-phase arrest, apoptosis, and GSDME-dependent cell death in vitro and in vivo.
Topics: Apoptosis; Bone Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Diosgenin; G2 Phase Cell Cycle Checkpoints; Humans; Osteosarcoma; Pyroptosis; Receptors, Estrogen | 2020 |
Dioscin inhibits stem-cell-like properties and tumor growth of osteosarcoma through Akt/GSK3/β-catenin signaling pathway.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; beta Catenin; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Child; Diosgenin; Female; Glycogen Synthase Kinase 3; Humans; Male; Mice; Mice, Nude; Middle Aged; Neoplastic Stem Cells; Osteosarcoma; Proto-Oncogene Proteins c-akt; Signal Transduction; Young Adult | 2018 |